Research Digest
Retatrutide: what the trials actually measured, reviewed in plain language.
A Phase 1-to-Phase-3 walk through the published evidence on a triple-receptor agonist that produced the largest weight-loss figures ever seen in a pharmacotherapy trial — and a clear-eyed account of what is still unknown.
The short version
Retatrutide is an experimental drug that targets three hormone receptors at the same time — GLP-1, GIP, and glucagon. Those are the same appetite-regulating hormones that other weight-loss medicines target, but retatrutide hits all three at once, which researchers think is why it produces larger weight loss than anything that has come before it.
In a Phase 2 trial — a mid-stage research study involving 338 adults with obesity — participants taking the highest dose lost an average of 24.2% of their body weight over 48 weeks [1]. That is a larger number than any previously approved obesity medicine has achieved.
The catch: retatrutide is not approved anywhere in the world as of 2026. It is still in Phase 3 clinical trials (large, late-stage studies that must be completed before a medicine can seek regulatory approval). It is not available by prescription. This site is a review of the published research, not a place to obtain the compound. For a full account of what people report using it — including the downsides — see the effects page.
What does retatrutide do
Retatrutide works by activating three receptors that normally respond to hormones released by the gut after eating. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are called incretins — gut hormones that tell the pancreas to release insulin and tell the brain to feel full. Glucagon is a separate hormone made by the pancreas that raises blood glucose and, when activated in a controlled way, ramps up energy expenditure (how many calories the body burns at rest).
Most existing GLP-1-class medicines activate only the GLP-1 receptor. Tirzepatide, the next-generation agent approved for obesity and type 2 diabetes, activates both GLP-1R and GIPR (a dual agonist). Retatrutide adds the glucagon receptor on top, making it a triple agonist.
The theory — and the Phase 2 data appear to support it — is that the glucagon arm drives additional caloric expenditure on top of the appetite suppression from GLP-1 and GIP. The cryo-EM structural data published in 2024 confirmed that retatrutide binds all three receptors simultaneously, with particularly high potency at the GIP receptor (approximately 8.9 times more potent than native GIP) [3].
How does retatrutide work
At the molecular level, retatrutide is a 39-amino-acid synthetic peptide. It was engineered on a GIP-based backbone and modified with a fatty-acid chain that causes it to bind to albumin (the main protein in blood), which is what gives it an approximately 6-day half-life and allows it to be dosed once weekly [4].
When the molecule binds GLP-1R, it reduces appetite and slows gastric emptying (the rate at which food leaves the stomach). When it binds GIPR, it enhances insulin secretion after meals and modulates fat cell metabolism. When it binds the glucagon receptor (GCGR), it increases the liver's fat breakdown and raises resting energy expenditure. The combination of less food coming in and more energy going out is the proposed mechanism for the trial's large weight-loss results.
This triple-receptor design also explains one of retatrutide's consistent side effects: a dose-dependent increase in resting heart rate. Glucagon receptor activation raises heart rate via cAMP/PKA signaling — the same pathway that adrenaline uses [8]. This effect peaked at around 24 weeks in the Phase 2 trial, then partially plateaued [1].
What the Phase 2 trials found
Two major Phase 2 trials have reported results. The first, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity. Participants taking 12 mg once weekly lost a mean 24.2% of body weight over 48 weeks, compared with 2.1% in the placebo group [1]. Eighty-three percent of those on 12 mg lost more than 15% of body weight — a threshold considered clinically meaningful in obesity research.
The second Phase 2 trial, published in the Lancet in 2023, enrolled 281 adults with type 2 diabetes. At 36 weeks, the 12 mg group had reduced HbA1c (a measure of blood-sugar control) by 2.02% and body weight by 16.94%, compared with 0.01% and 3.0% respectively in the placebo group [2]. No severe hypoglycemia (dangerously low blood sugar) was reported.
A separate Phase 2 substudy in people with metabolic liver disease (MASLD, also called fatty liver disease) found that 12 mg reduced liver fat by 82.4% at 24 weeks, with 86% of participants reaching a normal fat level [5].
These figures come from controlled clinical trials with screened populations, medical oversight, and dose escalation protocols. Retatrutide research goes deeper on the mechanism and Phase 3 data.
Where things stand in Phase 3
Eli Lilly is running a Phase 3 program called TRIUMPH. Published results from TRANSCEND-T2D-1 (a Phase 3 trial in 537 adults with type 2 diabetes) showed retatrutide 12 mg reduced HbA1c by 1.94% and body weight by 15.3% versus 0.81% and 2.6% in the placebo group over 40 weeks, with adverse events predominantly mild-to-moderate GI effects and no severe hypoglycemia [12].
Dedicated cardiovascular and kidney outcomes trials are ongoing and have not yet reported results. Until those trials conclude and Eli Lilly submits for regulatory approval, retatrutide remains investigational — not approved, not prescribable, not available as a commercial medicine. See retatrutide results for a complete summary of the clinical trial record.
For a comparison with the currently-approved dual agonist, see retatrutide vs tirzepatide.